Xu, Duo

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 16.

Journal Article

Yang, Haitang; Gao, Yanyun; Xu, Duo; Xu, Ke; Shun-Qing, Liang; Yang, Zhang; Scherz, Amina; Hall, Sean R R; Forster, Stefan; Berezowska, Sabina; Yao, Feng; Ochsenbein, Adrian F; Marti, Thomas M; Kocher, Gregor J; Schmid, Ralph A; Dorn, Patrick; Peng, Ren-Wang (2023). MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma. Cell death discovery, 9(1), p. 55. Nature 10.1038/s41420-023-01307-2

Xu, Duo; Liu, Shengchen; Wu, Xi; Marti, Thomas M; Dorn, Patrick; Schmid, Ralph A; Peng, Ren-Wang; Shu, Yongqian (2022). Dissecting the Immunological Profiles in NSD3-Amplified LUSC through Integrative Multi-Scale Analyses. Cancers, 14(20) MDPI AG 10.3390/cancers14204997

Yang, Zhang; Liang, Shun-Qing; Saliakoura, Maria; Yang, Haitang; Vassella, Erik; Konstantinidou, Georgia; Tschan, Mario; Hegedüs, Balazs; Zhao, Liang; Gao, Yanyun; Xu, Duo; Deng, Haibin; Marti, Thomas M; Kocher, Gregor J; Wang, Wenxiang; Schmid, Ralph A; Peng, Ren-Wang (2021). Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer. EMBO molecular medicine, 13(9), e13193. EMBO Press 10.15252/emmm.202013193

Yang, Zhang; Liang, Shun-Qing; Yang, Haitang; Xu, Duo; Bruggmann, Rémy; Gao, Yanyun; Deng, Haibin; Berezowska, Sabina; Hall, Sean R R; Marti, Thomas M; Kocher, Gregor J; Zhou, Qinghua; Schmid, Ralph A; Peng, Ren-Wang (2021). CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for FGFR1-Amplified Lung Cancer. Cancer research, 81(11), pp. 3121-3133. American Association for Cancer Research AACR 10.1158/0008-5472.CAN-20-2276

Gao, Yanyun; Zens, Philipp; Su, Min; Gemperli, Camila Anna; Yang, Haitang; Deng, Haibin; Yang, Zhang; Xu, Duo; Hall, Sean R R; Berezowska, Sabina; Dorn, Patrick; Peng, Ren-Wang; Schmid, Ralph Alexander; Wang, Wenxiang; Marti, Thomas Michael (2021). Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR). Journal of experimental & clinical cancer research, 40(1), pp. 1-22. BioMed Central 10.1186/s13046-021-01938-2

Xu, Duo; Liang, Shun-Qing; Yang, Zhang; Yang, Haitang; Bruggmann, Rémy; Oberhaensli, Simone; Berezowska, Sabina; Marti, Thomas M; Hall, Sean R R; Dorn, Patrick; Kocher, Gregor J; Schmid, Ralph A; Peng, Ren-Wang (2021). Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis. Cell death & disease, 12(4), p. 406. Nature Publishing Group 10.1038/s41419-021-03668-x

Yang, Haitang; Xu, Duo; Yang, Zhang; Yao, Feng; Zhao, Heng; Schmid, Ralph A.; Peng, Ren-Wang (2020). Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. Cancers, 12(8) MDPI AG 10.3390/cancers12082310

Yang, Haitang; Xu, Duo; Gao, Yanyun; Schmid, Ralph; Peng, Ren-Wang (2020). Oncolytic Viral Therapy for Malignant Pleural Mesothelioma. Journal of thoracic oncology, 15(7), e111-e113. Elsevier 10.1016/j.jtho.2020.03.007

Xu, Duo; Shun-Qing, Liang; Yang, Haitang; Bruggmann, Rémy; Berezowska, Sabina; Zhang, Yang; Marti, Thomas; Hall, Sean Ralph Robert; Gao, Yanyun; Kocher, Gregor J.; Schmid, Ralph A.; Peng, Ren-Wang (2020). CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma. Molecular cancer therapeutics, 19(2), pp. 661-672. American Association for Cancer Research AACR 10.1158/1535-7163.MCT-19-0724

Yang, Haitang; Xu, Duo; Gao, Yanyun; Schmid, Ralph A.; Peng, Ren-Wang (2020). The Association of BAP1 Loss-of-Function With the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy. Journal of thoracic oncology, 15(6), e88-e90. Elsevier 10.1016/j.jtho.2020.02.028

Yang, Haitang; Xu, Duo; Schmid, Ralph A.; Peng, Ren-Wang (2020). Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma. Therapeutic advances in medical oncology, 12, p. 1758835920971421. Sage 10.1177/1758835920971421

Xu, Duo; Yang, Haitang; Schmid, Ralph A.; Peng, Ren-Wang (2020). Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight. Frontiers in oncology, 10, p. 579464. Frontiers Research Foundation 10.3389/fonc.2020.579464

Xu, Duo; Yang, Haitang; Zhang, Yang; Berezowska, Sabina; Gao, Yanyun; Shun-Qing, Liang; Marti, Thomas M.; Hall, Sean R. R.; Dorn, Patrick; Kocher, Gregor J.; Schmid, Ralph A.; Peng, Ren-Wang (2019). Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. Cancers, 11(10) MDPI AG 10.3390/cancers11101502

Yang, Haitang; Shun-Qing, Liang; Xu, Duo; Zhang, Yang; Marti, Thomas M.; Gao, Yanyun; Kocher, Gregor J.; Zhao, Heng; Schmid, Ralph A.; Peng, Ren-Wang (2019). HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer. Oncogenesis, 8(9), p. 45. Springer Nature 10.1038/s41389-019-0158-7

Shun-Qing, Liang; Bührer, Elias; Berezowska, Sabina Anna; Marti, Thomas; Xu, Duo; Froment, Laurène; Yang, Haitang; Hall, Sean; Vassella, Erik; Zhang, Yang; Kocher, Gregor; Amrein, Michael Alex; Riether, Carsten; Ochsenbein, Adrian; Schmid, Ralph; Peng, Ren-Wang (2019). mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. Oncogene, 38(5), pp. 622-636. Nature Publishing Group 10.1038/s41388-018-0479-6

Xu, Duo; Shun-Qing, Liang; Yang, Haitang; Lüthi, Ursina; Riether, Carsten; Berezowska, Sabina Anna; Marti, Thomas; Hall, Sean; Bruggmann, Rémy; Kocher, Gregor; Schmid, Ralph; Peng, Ren-Wang (2018). Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. British journal of cancer, 119(1), pp. 65-75. Nature Publishing Group 10.1038/s41416-018-0145-3

This list was generated on Fri Apr 19 10:15:10 2024 CEST.
Provide Feedback